Literature DB >> 21691255

Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2).

Vandana Megaraj1, Tianyong Zhao, Christian M Paumi, Phillip M Gerk, Richard B Kim, Mary Vore.   

Abstract

BACKGROUND: Multidrug resistance-associated protein 2 (MRP2; ABCC2) mediates the biliary excretion of glutathione, glucuronide, and sulfate conjugates of endobiotics and xenobiotics. Single nucleotide polymorphisms (SNPs) of MRP2 contribute to interindividual variability in drug disposition and ultimately in drug response.
OBJECTIVES: To characterize the transport function of human wild-type (WT) MRP2 and four SNP variants, S789F, A1450T, V417I, and T1477M.
METHODS: The four SNP variants were expressed in Sf9 cells using recombinant baculovirus infection. The kinetic parameters [Km, (μmol/l); V(max), (pmol/mg/min); the Hill coefficient] of ATP-dependent transport of leukotriene C(4) (LTC(4)), estradiol-3-glucuronide (E(2)3G), estradiol-17β-glucuronide (E(2)17G), and tauroursodeoxycholic acid (TUDC) were determined in Sf9-derived plasma membrane vesicles. Transport activity was normalized for expression level.
RESULTS: The V(max) for transport activity was decreased for all substrates for S789F, and for all substrates except E(2)17G for A1450T. V417I showed decreased apparent affinity for LTC(4), E(2)3G, and E(2)17G, whereas transport was similar between wild-type (WT) and T1477M, except for a modest increase in TUDC transport. Examination of substrate-stimulated MRP2-dependent ATPase activity of S789F and A1450T, SNPs located in MRP2 nucleotide-binding domains (NBDs), demonstrated significantly decreased ATPase activity and only modestly decreased affinity for ATP compared with WT.
CONCLUSION: SNPs in the NBDs (S789F in the D-loop of NBD1, or A1450T near the ABC signature motif of NBD2) variably decreased the transport of all substrates. V417I in membrane spanning domain 1 selectively decreased the apparent affinity for the glutathione and glucuronide conjugated substrates, whereas the T1477M SNP in the carboxyl terminus altered only TUDC transport.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691255      PMCID: PMC3640355          DOI: 10.1097/FPC.0b013e328348c786

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  58 in total

1.  Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.

Authors:  Sierk Haenisch; Karen May; Danilo Wegner; Amke Caliebe; Ingolf Cascorbi; Werner Siegmund
Journal:  Pharmacogenet Genomics       Date:  2008-04       Impact factor: 2.089

2.  Identification of regions required for apical membrane localization of human multidrug resistance protein 2.

Authors:  Paul E Bandler; Christopher J Westlake; Caroline E Grant; Susan P C Cole; Roger G Deeley
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

3.  Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2).

Authors:  Noam Zelcer; Maarten T Huisman; Glen Reid; Peter Wielinga; Pauline Breedveld; Annemieke Kuil; Puck Knipscheer; Jan H M Schellens; Alfred H Schinkel; Piet Borst
Journal:  J Biol Chem       Date:  2003-04-17       Impact factor: 5.157

4.  Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate.

Authors:  Phillip M Gerk; Wei Li; Vandana Megaraj; Mary Vore
Journal:  J Pharmacol Exp Ther       Date:  2006-11-15       Impact factor: 4.030

Review 5.  The apical conjugate efflux pump ABCC2 (MRP2).

Authors:  Anne T Nies; Dietrich Keppler
Journal:  Pflugers Arch       Date:  2006-07-18       Impact factor: 3.657

6.  Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy.

Authors:  Silvia Sookoian; Gustavo Castaño; Adriana Burgueño; Tomas Fernández Gianotti; Carlos J Pirola
Journal:  J Hepatol       Date:  2007-10-23       Impact factor: 25.083

Review 7.  Structure and mechanism of ABC transporter proteins.

Authors:  Kaspar Hollenstein; Roger J P Dawson; Kaspar P Locher
Journal:  Curr Opin Struct Biol       Date:  2007-08-27       Impact factor: 6.809

Review 8.  Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).

Authors:  Ulrike Gradhand; Richard B Kim
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

9.  Charged amino acids in the sixth transmembrane helix of multidrug resistance protein 1 (MRP1/ABCC1) are critical determinants of transport activity.

Authors:  Anass Haimeur; Roger G Deeley; Susan P C Cole
Journal:  J Biol Chem       Date:  2002-08-18       Impact factor: 5.157

10.  MRP2 haplotypes confer differential susceptibility to toxic liver injury.

Authors:  Ji Ha Choi; Byung Min Ahn; Jihyun Yi; Ji Hyun Lee; Jeong Ho Lee; Soon Woo Nam; Chae Yoon Chon; Kwang-Hyub Han; Sang Hoon Ahn; In-Jin Jang; Joo-Youn Cho; Yousin Suh; Mi-Ook Cho; Jong-Eun Lee; Kyung Hwan Kim; Min Goo Lee
Journal:  Pharmacogenet Genomics       Date:  2007-06       Impact factor: 2.089

View more
  11 in total

1.  In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Authors:  Xia Wen; Melanie S Joy; Lauren M Aleksunes
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

2.  Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.

Authors:  Vineetha Koroth Edavana; Rosalind B Penney; Aiwei Yao-Borengasser; Athena Starlard-Davenport; Ishwori B Dhakal; Susan Kadlubar
Journal:  Int J Cancer Res Mol Mech       Date:  2015-09-22

3.  Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics.

Authors:  Mayakannan Manikandan; Arasambattu Kannan Munirajan
Journal:  OMICS       Date:  2013-11-28

4.  Single nucleotide polymorphisms in microRNA binding sites: implications in colorectal cancer.

Authors:  Panchalee Bhaumik; Chandrasekhar Gopalakrishnan; Balu Kamaraj; Rituraj Purohit
Journal:  ScientificWorldJournal       Date:  2014-12-24

5.  Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.

Authors:  Karolina Tecza; Jolanta Pamula-Pilat; Joanna Lanuszewska; Dorota Butkiewicz; Ewa Grzybowska
Journal:  Oncotarget       Date:  2018-01-10

6.  Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.

Authors:  Maud Maillard; Christine Chevreau; Félicien Le Louedec; Manon Cassou; Caroline Delmas; Laure Gourdain; Jean-Yves Blay; Didier Cupissol; Emmanuelle Bompas; Antoine Italiano; Nicolas Isambert; Corinne Delcambre-Lair; Nicolas Penel; François Bertucci; Cécile Guillemet; Julien Plenecassagnes; Stéphanie Foulon; Étienne Chatelut; Axel Le Cesne; Fabienne Thomas
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

7.  In vitro Transport Ability of ABCC2 (G1249A) Polymorphic Variant Towards Anticancer Drugs.

Authors:  Guo Lian; Jia Yuan; Yuan Gao
Journal:  Onco Targets Ther       Date:  2020-02-17       Impact factor: 4.147

8.  A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China.

Authors:  Lina Wu; Yanmeng Li; Yi Song; Donghu Zhou; Siyu Jia; Anjian Xu; Wei Zhang; Hong You; Jidong Jia; Jian Huang; Xiaojuan Ou
Journal:  Orphanet J Rare Dis       Date:  2020-03-18       Impact factor: 4.123

Review 9.  Clinical Perspectives on Targeting Therapies for Personalized Medicine.

Authors:  Donald R J Singer; Zoulikha M Zaïr
Journal:  Adv Protein Chem Struct Biol       Date:  2015-12-29       Impact factor: 3.507

Review 10.  Pharmacogenetics of Statin-Induced Myotoxicity.

Authors:  Ping Siu Kee; Paul Ken Leong Chin; Martin A Kennedy; Simran D S Maggo
Journal:  Front Genet       Date:  2020-10-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.